Mounjaro® (Tirzepatide)
A New Era in Weight Management and Diabetes Care
First-in-class dual GIP/GLP-1 receptor agonist delivering superior outcomes in both glycemic control and weight management
Weight Loss
HbA1c Reduction
Injection
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a first-in-class, once-weekly injectable medication developed by Eli Lilly. It was approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in May 2022, and more recently (as Zepbound) for chronic weight management in November 2023.
While primarily launched in the U.S., Mounjaro is gaining global traction with ongoing applications and approvals in Canada, the EU, Japan, and India.
Key Indications
- Adults with type 2 diabetes
- Adults with obesity (BMI ≥30)
- Overweight (BMI ≥27) with comorbidities
Tirzepatide: A Dual Incretin Receptor Agonist
GLP-1 Receptor Agonism
- Delayed gastric emptying
- Central appetite suppression
- Increased insulin secretion
- Reduced glucagon levels
GIP Receptor Agonism
- Synergistic with GLP-1
- Improved insulin sensitivity
- Greater weight reduction
- Enhanced fat mass reduction
Dual Mechanism Benefits
- Enhanced insulin secretion
- Improved glucose utilization
- Greater appetite suppression
- Increased fat oxidation
Unique Advantage: This dual mechanism is unique and provides enhanced effects on appetite suppression, insulin sensitivity, and glucose regulation, compared to traditional GLP-1-only therapies. This complementary pathway activation distinguishes tirzepatide from existing single-incretin agents.
The Clinical Foundation of Tirzepatide
The efficacy and safety of tirzepatide have been extensively evaluated in several large, multicenter, phase 3 clinical trials, most notably the SURMOUNT and SURPASS programs. These studies provide a robust evidence base supporting its use in both obesity management and type 2 diabetes mellitus (T2DM).
SURMOUNT-1 Trial (NEJM, 2022)
The SURMOUNT-1 trial was a pivotal randomized, double-blind, placebo-controlled study that
assessed the impact of tirzepatide on body weight in 2,539 adults who had obesity (BMI ≥30 kg/m²)
or were overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (excluding type 2
diabetes).
Over a 72-week treatment period, participants receiving tirzepatide 15 mg achieved an average
weight loss of 22.5%, translating to approximately 23.6 kg, a clinically significant reduction compared
to the 2.4% weight loss observed in the placebo group. Notably, 85% to 91% of patients receiving
tirzepatide achieved at least 5% body weight reduction, a threshold often used to define
clinically meaningful weight loss. These results established tirzepatide as one of the most effective
pharmacotherapies for obesity to date.
Population:
2,539 adults with obesity (BMI ≥30) or overweight with ≥1 comorbidity (excluding T2DM)
Key Results:
- Mean weight loss of 22.5% with tirzepatide 15 mg at 72 weeks
- 85–91% of patients achieved ≥5% weight loss
- Placebo group lost only ~2.4%
SURMOUNT-2 Trial (NEJM, 2023)
Building on the SURMOUNT-1 findings, the SURMOUNT-2 trial evaluated tirzepatide in
individuals with both obesity and type 2 diabetes. Participants received either 10 mg or 15 mg
tirzepatide once weekly for 72 weeks.
The results were compelling: those in the 10 mg group lost an average of 12.8% of their body
weight, while those in the 15 mg group lost 14.7%. In addition to weight loss, patients experienced
substantial improvements in glycemic control, with HbA1c reductions of up to 2.3 percentage
points. The dual benefits of effective weight reduction and glycemic improvement highlight
tirzepatide's value in the management of patients with type 2 diabetes and coexisting obesity.
Population:
Adults with T2DM and obesity
Key Results:
- Weight reduction: 12.8% (10 mg) and 14.7% (15 mg)
- HbA1c improved by up to 2.3 percentage points
- Dual benefits of weight reduction and glycemic improvement
SURPASS Trials Overview
The SURPASS program, a series of trials focused primarily on glycemic outcomes in patients with
type 2 diabetes, further confirmed tirzepatide's superiority over current standard therapies.
Across multiple studies comparing tirzepatide to agents such as insulin glargine, insulin degludec,
and semaglutide 1 mg, tirzepatide consistently delivered greater reductions in HbA1c (up to
2.5%) and body weight loss of up to 13%. At the 15 mg weekly dose, patients experienced an average
HbA1c reduction of 2.34% and lost as much as 10.5 kg in body weight. Even at the lower 5 mg dose,
patients saw improvements of 2.11% in HbA1c and 5.4 kg in weight loss.
Collectively, these trials establish tirzepatide as a highly efficacious treatment in both the
obesity and diabetes space, outperforming GLP-1 receptor agonists, including
semaglutide, in terms of both weight reduction and glycemic control.
Key Findings:
- Up to 13% body weight loss in patients with T2DM
- Superior to insulin glargine, insulin degludec, and semaglutide 1 mg
- Consistent across multiple dose levels
Dose-Response Results:
- 5mg/week: HbA1c reduction of -2.11%; weight loss 5.4 kg
- 15mg/week: HbA1c reduction of -2.34%; weight loss 10.5 kg
Benefits of Using Mounjaro (Tirzepatide)
Metabolic Impact
- Appetite Regulation: Acts centrally on hypothalamic appetite centers, reducing hunger and food cravings
- Fat Metabolism: Improves lipid profiles, increases adiponectin, and shifts metabolism toward fat utilization
Effective Glycemic Control
- FDA-approved as adjunct to diet and exercise for T2DM
- Can be used as monotherapy when metformin is contraindicated
- Significantly greater HbA1c reductions vs established therapies
Significant and Consistent Weight Loss
- Up to 22.5% body weight reduction over 72 weeks
- Over 81% of users achieved ≥5% weight loss within a year
- Effective for both diabetic and non-diabetic individuals
Convenient Dosing
- Once-weekly subcutaneous injection
- Flexible dosing from 2.5 mg up to 15 mg
- Auto-injector pens for easy administration
Summary Table: Key Benefits
| Benefit | Evidence/Source |
|---|---|
| Metabolic Impact | Appetite Regulation and Fat Metabolism |
| Glycemic Control | Dual GLP-1/GIP mechanism—HbA1c reduced >2% |
| Weight Reduction | Up to 22.5% loss in 72 weeks (SURMOUNT-1) |
| Cardiometabolic Benefits | Reduces blood pressure, visceral adiposity, circulating triglycerides |
| High Responder Rate | ~81.8% achieving ≥5% weight loss (vs. 66.5% semaglutide users) |
| Once-Weekly Dosing | FDA-labelled regimen from 2.5 to 15 mg weekly |
| Surgical Alternative | Comparable weight-loss outcomes; avoids surgical risks |
| Long-Term Maintenance | Sustained efficacy; weight regain after discontinuation reported |
How Mounjaro Differs from Other Medications
| Feature | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) | Saxenda (Liraglutide) |
|---|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only | GLP-1 receptor agonist only |
| FDA Approved For | T2DM, Obesity | T2DM, Obesity | Obesity |
| Weight Loss | ~22.5% reduction | ~14.9% reduction | ~8% reduction |
| Dosing | Once weekly injection | Once weekly injection | Daily injection |
Tirzepatide clearly outperforms semaglutide in direct head-to-head weight loss trials, making it the most effective pharmacologic weight loss agent currently available.
Guidelines for Safe Use of Mounjaro (Tirzepatide) Injection
Adult Dosing Schedule
- Starting dose: 2.5 mg once weekly for the first 4 weeks (for initiation, not glycemic control)
- Maintenance: Increase to 5 mg once weekly after 4 weeks
- Titration: If needed, increase by 2.5 mg increments every 4 weeks based on HbA1c, weight reduction, and tolerability
- Maximum dose: 15 mg once weekly
Available Strengths
- 2.5 mg / 0.5 mL
- 5 mg / 0.5 mL
- 7.5 mg / 0.5 mL
- 10 mg / 0.5 mL
- 12.5 mg / 0.5 mL
- 15 mg / 0.5 mL
Administration Instructions
Injection Sites:
- Abdomen (avoid 2-inch radius around navel)
- Front of the thigh
- Back of the upper arm
Key Points:
- Once weekly, same day each week
- Any time of day, with or without food
- Rotate injection sites
- Store in refrigerator (2°C–8°C)
Special Populations
Pediatric Use:
Safety and effectiveness in patients under 18 years have not been established.
Older Adults:
Efficacy and safety were consistent with younger populations in clinical trials, though older adults may show increased sensitivity.
Side Effects and Contraindications
Common Side Effects
Generally self-limiting and most commonly occur during initial weeks:
- Nausea
- Vomiting
- Reduced appetite
- Stomach upset or indigestion
- Constipation or diarrhea
- Injection site reactions
- Skin rash or itching
Serious Adverse Effects
Require immediate medical attention:
- Acute Kidney Injury - Often secondary to dehydration
- Diabetic Retinopathy Worsening - Especially with rapid glycemic improvements
- Gallbladder Disorders - Including cholelithiasis and cholecystitis
- Severe Appetite Suppression - Leading to undernutrition
- Abdominal Pain or Bloating
- Tachycardia - Increased heart rate
- Acute Pancreatitis - Particularly in post-bariatric surgery patients
Contraindications
- Hypersensitivity: Known hypersensitivity to tirzepatide, excipients, or benzyl alcohol
- Thyroid C-Cell Tumors: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and Lactation: Contraindicated due to absence of safety data and evidence of reproductive toxicity in animal studies
Warnings and Precautions
- Allergic Reaction: Each dose contains 5.4 mg benzyl alcohol
- Thyroid Tumor Risk: Monitor for neck swelling or trouble swallowing
- Cardiovascular Effects: May increase heart rate
- Hypoglycemia Risk: When used with insulin or sulfonylureas
- Gastrointestinal: Not recommended for severe gastroparesis
- Mental Health: Monitor for depressive symptoms or suicidal ideation
Important Safety Information
- Not approved for use in type 1 diabetes mellitus (T1DM)
- Has not been studied in patients with a history of pancreatitis
- Women of childbearing potential should use effective contraception during treatment
- Discontinue Mounjaro at least one month before planned conception
Who Can Use Mounjaro? Clinical Suitability and Prescription Requirements
Clinical Eligibility Criteria
According to clinical guidelines and regulatory indications, Mounjaro may be prescribed for weight management in the following individuals:
Primary Indication:
- Adults with BMI ≥30 kg/m² (obese), regardless of comorbid conditions
Secondary Indication:
- Adults with BMI ≥27 kg/m² (overweight) plus at least one weight-related comorbidity
Weight-Related Comorbidities Include:
- Type 2 diabetes
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
Prescription Guidelines in India
In India, Mounjaro (tirzepatide) is approved for the treatment of type 2 diabetes in adults as an adjunct to diet and exercise.
Key Points:
- Only MBBS/MD-registered practitioners can prescribe
- Valid prescription required for dispensing
- Off-label use must be supported by clinical evidence
- Informed consent required for off-label prescribing
Access and Availability in India
Where to Purchase:
- Registered retail pharmacies with valid prescription
- Online pharmacy platforms (Tata 1mg, Netmeds, Apollo Pharmacy)
Storage Requirements:
- Store in refrigerator (2°C–8°C)
- Available in KwikPen form
- Follow proper handling instructions
Start Mounjaro Safely
Before starting Mounjaro, it is essential to consult a licensed physician, preferably an endocrinologist or obesity specialist. A medical consultation ensures that the treatment is safe and appropriate based on your medical history, BMI, comorbidities, and other medications.
Medical Consultation Process
During the consultation, the physician will:
- Evaluate your BMI and metabolic risk
- Discuss benefits vs risks
- Initiate the appropriate starting dose (2.5 mg once weekly)
- Schedule regular follow-ups for dose adjustment and monitoring
Avoid Self-Medication
Mounjaro requires clinical oversight to prevent adverse effects like pancreatitis, gallbladder issues, and severe gastrointestinal events.
Teleconsultation Available
With the rise of digital health services, teleconsultation platforms in India now offer remote access to certified doctors for Mounjaro evaluation and prescription.
Convenient remote consultations with qualified specialists
FAQ - Mounjaro for Weight Loss
Can I take Mounjaro without diabetes?
Yes—clinical trials like SURMOUNT-1 have demonstrated that Mounjaro is effective for weight loss in people without diabetes. It is currently approved for weight loss in several countries (e.g., the US under the name Zepbound) for adults with a BMI ≥30, or a BMI ≥27 with weight-related comorbidities.
How long does it take to show results?
Most patients begin to see changes within 4–8 weeks, with noticeable weight loss typically observed by week 12. The full effects develop over 6–12 months, depending on dosage and adherence to lifestyle changes.
Is it a lifetime medication?
Not necessarily. Mounjaro is used as a long-term therapy, but the duration depends on treatment goals, response, side effects, and medical supervision. It may be tapered off once the target weight or glycemic control is achieved and sustained with lifestyle alone.
Will I gain weight after stopping?
Some weight regain is possible after discontinuation, especially if dietary and physical activity changes are not maintained. Studies suggest weight regain varies by individual but may range from 5–10% of lost weight within a year of stopping. Ongoing lifestyle support is critical to maintain results.
Why Is Mounjaro Gaining Global Popularity?
Mounjaro (tirzepatide) is gaining widespread popularity across the globe due to its remarkable efficacy in both type 2 diabetes management and weight loss.
Even before its formal approval for weight management, Mounjaro was being widely prescribed off-label for people with obesity and related metabolic conditions. Real-world patient experiences, shared widely on social media and support platforms, have further boosted its reputation and demand.
Endocrinologists and obesity experts have embraced Mounjaro as a breakthrough therapy, making it a preferred option in the evolving landscape of metabolic disease management.
Global Recognition
Breakthrough therapy embraced by healthcare professionals worldwide
Conclusion
Mounjaro (tirzepatide) represents a paradigm shift in obesity and diabetes care. Its dual incretin mechanism enables powerful appetite suppression, improved insulin sensitivity, and meaningful reductions in body fat and glucose levels.
Backed by robust Phase 3 trial data, tirzepatide provides a highly effective, non-surgical solution for weight management with added metabolic benefits. Its unique pharmacologic profile sets it apart as the most promising anti-obesity agent to date.
Most Effective
Pharmacologic weight loss agent currently available
References
- U.S. Food and Drug Administration. FDA Drug Approval: Tirzepatide (Mounjaro). Silver Spring (MD): FDA; 2022.
- U.S. Food and Drug Administration. FDA Approval: Zepbound for Obesity. FDA Press Release. 2023 Nov.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
- Drucker DJ. Advances in incretin-based therapies. J Clin Invest. 2021;131(1):e142941.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
- Frías JP, et al. Tirzepatide for obesity in type 2 diabetes: SURMOUNT-2 trial. N Engl J Med. 2023;388:1839–52.
- Rosenstock J, Wysham C, Frías JP, et al. Tirzepatide vs insulin glargine in type 2 diabetes: SURPASS-4 trial. Lancet. 2021;398(10295):1811–24.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide on weight loss maintenance in adults with overweight or obesity: STEP 4 trial. Lancet. 2021;397(10271):971–84.
- Nauck MA, Meier JJ. Incretin therapies: highlighting common features and differences in the mechanisms of action. Diabetologia. 2019;62(10):1751–64.
- Samms RJ, Christe ME, Collins KA, et al. GIPR agonism improves insulin sensitivity and body weight. JCI Insight. 2017;2(6):e93407.
- Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Neuroendocrine mechanisms of appetite regulation. Nat Rev Endocrinol. 2021;17(11):639–55.
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide on metabolic endpoints in type 2 diabetes. Diabetes Care. 2022;45(5):1212–20.
- Pace Hospitals. Mounjaro Injection – Uses, Side Effects, Dosage, and Composition [Internet].
- Weill Cornell Medicine. Tirzepatide enhances weight loss with sustained treatment. 2023 Dec.
- JAMA Network Open. Weight regain after discontinuation of tirzepatide. JAMA Netw Open. 2024.
- Frías JP, et al. Tirzepatide for the treatment of obesity in people with type 2 diabetes. N Engl J Med. 2023;388:1839–52.
- American Association of Clinical Endocrinology (AACE). Clinical Practice Guidelines for Obesity – 2023 Update.
- Coskun T, Sloop KW, Loghin C, et al. Tirzepatide: A dual GIP/GLP-1 receptor agonist for treatment of type 2 diabetes. J Clin Invest. 2021;131(10):e145166.
- Garvey WT, Mechanick JI, Brett EM, et al. Two-year effects of tirzepatide on weight and cardiometabolic measures in adults with obesity. Obesity (Silver Spring). 2023;31(4):812–21.
- Kushner RF, Calhoun DA, McMahon G, Garvey WT. Weight regain after anti-obesity medications: clinical challenges and future directions. Obesity (Silver Spring). 2021;29(8):1235–42.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
